

Substitute for forms 1449A/PTO & 1449B/PTO

ATTORNEY'S DKT NO.

APPLICATION No. _____

017751-021

09/801.751

APPLICANT

Jean-Pierre ROBIN et al

FILING DATE

GROUP

March 9, 2001




1614

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS


[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes	No
	0393575		EP	10-27-1990	X	
	00/40269		WO	07-13-2000	X	
	02/32904		WO	10-17-2000	X	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>[Handwritten mark]</i>	U.S. Statutory Invention Registration H271, published May 5, 1987.
<i>[Handwritten mark]</i>	J M Whaun et al, "Treatment of Chloroquine-Resistant Malaria with Esters of Cephalotaxine Homoharringtonine," Ann Trop Med Parasitol, Vol. 84, No. 3, 1990, pp. 229-237.
<i>[Handwritten mark]</i>	H.M. Kantarjian et al, "Chronic myelogenous leukemia - Progress at the M. D. Anderson Cancer Center over the past two decades and future directions: First Emil J. Freireich Award Lecture," Clinical Cancer Research, 1997, pp. 2723-2733.
<i>[Handwritten mark]</i>	Vincent Levy et al, "Subcutaneous homoharringtonine (SQ HHT): 1. Pharmacokinetic study in dogs and HHT determination in blood in using LC-MS method," Blood, Vol. 98, NO. 11, part 2, November 16, 2001, pp. 179B. <i>ABSTRACT ONLY</i>
<i>[Handwritten mark]</i>	Vincent Levy et al, "Subcutaneous homoharringtonine (SQ HHT): 2. Tolerance in Humans and case report of a refractory patient with AML treated by very small dose of SQ HHT," Blood, Vol. 98, No. 11, Part 2, November 16, 2001, pp. 202B. <i>ABSTRACT ONLY</i>
<i>[Handwritten signature]</i>	

Examiner Signature		Date Considered	2/10/03
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

~~*~~ no copies.